Purpose

Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP). - The participant has a diagnosis of COVID-19 confirmed by COVID-19 PCR. - Patient is 18 years of age or older.

Exclusion Criteria

  • Participant declines to participate (living patients only) - Participant or healthcare surrogate is unable to provide informed consent (living patients only)

Study Design

Phase
Study Type
Observational
Observational Model
Other
Time Perspective
Other

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Luigi R Boccardi, BS
913-588-4022
lboccardi@kumc.edu

More Details

Status
Recruiting
Sponsor
University of Kansas Medical Center

Study Contact

Luigi R Boccardi, BS
9135884022
lboccardi@kumc.edu

Detailed Description

While SARS-CoV-2 has some similarities to the SARS-CoV pathogen that led to an epidemic in 2002 and 2003, there is much about the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of the novel virus that remains unknown.3 Additional research is needed to explore the nature of the virus, its spectrum of disease, and potential therapies to combat its spread. The aim of this project will be to establish a biorepository of blood samples from patients infected with SARS-CoV-2 that can then be used by investigators to expand our understanding of COVID-19 and its treatment and, in turn, improve patient outcomes. The COVID-19 biorepository will accomplish the following specific aims: 1. Establish a collection of biospecimens from patients with COVID-19. 2. Establish a link between biospecimens and longitudinal individual patient data, which will be collected and stored in RedCap. 3. Provide biospecimens and unique patient data to researchers investigating COVID-19. Separate IRB approval will be needed for these studies.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.